Your browser doesn't support javascript.
loading
Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue, Yong; Richards, Susan M; Mahmood, Asif; Cox, Gerald F.
Affiliation
  • Xue Y; Clinical Development, Rare Diseases Group, Sanofi Genzyme, Naarden, The Netherlands. Electronic address: yong.xue@genzyme.com.
  • Richards SM; Clinical Laboratory Sciences, Sanofi Genzyme, Framingham, MA, USA. Electronic address: susan.richards@genzyme.com.
  • Mahmood A; Global Pharmacovigilance and Epidemiology, Sanofi Genzyme, Cambridge, MA, USA. Electronic address: asif.mahmood@genzyme.com.
  • Cox GF; Clinical Development, Rare Diseases Group, Sanofi Genzyme, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: gerald.cox@genzyme.com.
Mol Genet Metab ; 117(4): 419-26, 2016 Apr.
Article in En | MEDLINE | ID: mdl-26920513

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis I / Enzyme Replacement Therapy / Iduronidase / Antibodies Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Mol Genet Metab Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Year: 2016 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidosis I / Enzyme Replacement Therapy / Iduronidase / Antibodies Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Mol Genet Metab Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA / METABOLISMO Year: 2016 Document type: Article Country of publication: United States